Why the study?
Retroperitoneal liposarcoma typically shows limited response to standard chemotherapy, presenting a challenge in treating advanced or metastatic disease.
Does combined therapy with eribulin, anlotinib, and camrelizumab improve progression-free survival in patients with advanced or metastatic retroperitoneal liposarcoma?
Does combined therapy with eribulin, anlotinib, and camrelizumab improve progression-free survival in patients with advanced or metastatic retroperitoneal liposarcoma?
The combination of eribulin, anlotinib, and camrelizumab demonstrated promising progression-free survival and manageable safety in advanced or metastatic retroperitoneal liposarcoma.
This is the authors' abstract. We don't add key points for this paper.
Background: Retroperitoneal liposarcoma (RLPS) typically shows limited response to standard chemotherapy, presenting a challenge in treating advanced or metastatic RLPS. Objective: This study aimed to evaluate the potential advantages of a combined therapeutic strategy utilizing eribulin, anlotinib, and camrelizumab. Design: Between December 2020 and March 2023, this retrospective study enrolled patients with advanced or metastatic RLPS who received treatment at Peking University Cancer Hospital Sarcoma Center. The treatment regimen involved eribulin plus anlotinib and camrelizumab administered every 3 weeks (Q3W). Methods: Efficacy was assessed following the Response Evaluation Criteria in Solid Tumors version 1.1, while safety was evaluated using the Common Terminology Criteria for Adverse Events version 5.0. Six patients underwent surgery before disease progression, and one patient with myxoid liposarcoma (MLPS) had a pathological complete response. With a median follow-up of 21.8 (range, 2.7-30.7) months, the median progression-free survival (mPFS) was 6.9 (95% confidence interval (CI), 4.7-9.1) months, and the 6-month PFS rate was 60.5%. Based on various histological subtypes, the mPFS was 8.4 (95% CI, 4.1-12.7) months with well-differentiated liposarcoma, 5.8 (95% CI, 3.3-8.3) months with de-differentiated liposarcoma and not reached with MLPS, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 36 (76.6%) patients, with grade 3 or higher TRAEs in 21 (44.7%) patients. The most common TRAEs were neutropenia (53.2%), proteinuria (21.3%), and anorexia (21.3%). Conclusion: The combined treatment strategy involving eribulin, anlotinib, and camrelizumab showed promising efficacy and manageable safety in patients with advanced or metastatic RLPS, particularly in those with MLPS.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open PFS benefit of this triplet in advanced retroperitoneal liposarcoma.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: